Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with β2-adrenergic agonists Elena Goleva, PhD, Annegret Dunlap, BS, Donald Y.M. Leung, MD, PhD Journal of Allergy and Clinical Immunology Volume 114, Issue 1, Pages 183-191 (July 2004) DOI: 10.1016/j.jaci.2004.04.001
Fig 1 PHA-induced proliferation of PBMCs from the healthy control group (A; n=6) or the allergic asthmatic group (B; n=5) in the presence of low concentrations of FP in combination with salmeterol. The data are presented as the percentages of proliferation compared with FP alone (defined as 100%). ∗P < .05, ∗∗P < .01 compared with FP only. Journal of Allergy and Clinical Immunology 2004 114, 183-191DOI: (10.1016/j.jaci.2004.04.001)
Fig 2 Salmeterol (10−7 mol/L) combination with suboptimal concentration of FP (10−12 mol/L) enhances GCR nuclear translocation in freshly isolated human PBMCs from healthy control subjects (D) but not from allergic asthmatic patients (C; 630×; blue, DAPI-nuclear staining; red, cy3-GCR). GCR localization in PBMCs from healthy donors before (A) or after (B) treatment with a suboptimal concentration of 10−12 mol/L FP (1 hour at 37°C) is shown as well. Journal of Allergy and Clinical Immunology 2004 114, 183-191DOI: (10.1016/j.jaci.2004.04.001)
Fig 3 Inhibition of PHA-induced IFN-γ and TNF-α production with a suboptimal concentration of FP (10−12 mol/L) in combination with salmeterol in PHA-stimulated supernatants from the healthy control group (A and C) or the allergic asthmatic group (B and D). ∗P < .05, ∗∗P < .01 compared with PHA only. Journal of Allergy and Clinical Immunology 2004 114, 183-191DOI: (10.1016/j.jaci.2004.04.001)
Fig 4 A, PHA-induced proliferation of PBMCs from allergic asthmatic patients in the presence of low concentrations of FP in combination with salmeterol and the PDE4 inhibitor rolipram. The data are presented as the percentages of proliferation compared with PHA alone (n=5). ∗P < .05 compared with FP only. B, Inhibition of IL-13 mRNA production by PBMCs from allergic asthmatic patients in the presence of FP-salmeterol-rolipram combination (n=7). Journal of Allergy and Clinical Immunology 2004 114, 183-191DOI: (10.1016/j.jaci.2004.04.001)
Fig 4 A, PHA-induced proliferation of PBMCs from allergic asthmatic patients in the presence of low concentrations of FP in combination with salmeterol and the PDE4 inhibitor rolipram. The data are presented as the percentages of proliferation compared with PHA alone (n=5). ∗P < .05 compared with FP only. B, Inhibition of IL-13 mRNA production by PBMCs from allergic asthmatic patients in the presence of FP-salmeterol-rolipram combination (n=7). Journal of Allergy and Clinical Immunology 2004 114, 183-191DOI: (10.1016/j.jaci.2004.04.001)